key: cord-0783057-mirdq4d0 authors: Yokoyama, Yujiro; Aikawa, Tadao; Takagi, Hisato; Briasoulis, Alexandros; Kuno, Toshiki title: Association of renin‐angiotensin‐aldosterone system inhibitors with mortality and testing positive of COVID‐19: Meta‐analysis date: 2020-10-30 journal: J Med Virol DOI: 10.1002/jmv.26588 sha: eda7d2c5f79c5ff4b85354e3f6ae3318118d5a00 doc_id: 783057 cord_uid: mirdq4d0 Some have hypothesized that the use of angiotensin‐converting enzyme inhibitors (ACEI) and angiotensin‐receptor blockers (ARB) may modify susceptibility to coronavirus disease‐2019 (COVID‐19) in humans. Thus, we conducted two meta‐analyses to investigate the effect of ACEI and ARB on mortality and susceptibility to COVID‐19. Pubmed and EMBASE were searched through June 2020 to identify clinical trials that investigated the testing positive and in‐hospital mortality rates for COVID‐19 for those who were treated with ACEI and/or ARB and for those who were not treated with ACEI or ARB. The first analysis investigated the testing positive rate of COVID‐19. The second analysis investigated the in‐hospital mortality rate for patients with COVID‐19. Three eligible studies for the first analysis and 14 eligible studies for the second analysis were identified. The first analysis demonstrated that the use of ACEI or ARB did not affect the testing positive rates (odds ratio [OR] [confidence interval [CI]] = 0.96 [0.88–1.04]; p = .69, OR [CI] = 0.99 [0.91–1.08]; p = 0.35, respectively). The second analysis showed that the use of ACEI and/or ARB did not affect in‐hospital mortality (risk ratio [RR] 95% [CI]] = 0.88 [0.64–1.20], p = 0.42). The subgroup analysis by limiting studies of patients with hypertension showed ACEI and/or ARB use was associated with a significant reduction of in‐hospital mortality compared with no ACEI or ARB use (RR [CI] = 0.66 [0.49‐0.89], p = 0.004). Our analysis demonstrated that ACEI and/or ARB use was associated neither with testing positive rates of COVID‐19 nor with mortality of COVID‐19 patients. Pubmed and EMBASE were searched through June 2020 to identify clinical trials that investigated the testing positive and in-hospital mortality rates for COVID-19 for those who were treated with ACEI and/or ARB and for those who were not treated with ACEI or ARB. The first analysis investigated the testing positive rate of COVID-19. The second analysis investigated the in-hospital mortality rate for patients with COVID-19. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), can infect host cells by means of interaction with membrane-bound angiotensin-converting enzyme 2 (ACE2) on respiratory epithelium. 1 ACE inhibitors (ACEI) and angiotensin-receptor blockers (ARB) are considered first-choice drugs for patients with hypertension, heart failure, and chronic kidney disease, but also increase the expression of ACE2. 2 Therefore, some have hypothesized that their use may modify susceptibility to infection with SARS-CoV-2 in humans. On the contrary, ACE2 expression is downregulated following SARS-1 infection, resulting in disproportionate activation of the renin-angiotensin-aldosterone system and exacerbated pneumonia progression. 3 However, there is no consensus as to whether their use might increase or reduce of severity or susceptibility for SARS-CoV-2 infection. Although several metaanalyses were conducted to assess the outcome of ACEI/ARB use on patients with COVID-19, 4-6 a large observational study using databases in Asia, Europe, and North America which was included in these meta-analyses, was retracted from a peer-reviewed journal. 7 Therefore, investigation of the effect of ACEI/ARB use on patients with COVID-19 is still warranted, hence we conducted two meta-analyses to compare mortality and susceptibility of SARS-CoV-2 infection between patients treated and those not treated with ACEI and/or ARB. All observational studies that investigated the testing positive and inhospital mortality rates for COVID-19 for those who were treated with ACEI or/and ARB and for those not treated with ACEI or ARB were identified using a two-level strategy. First, databases including Pubmed and EMBASE were searched through June 18, 2020. Second, relevant studies were identified through a manual search of secondary sources including references of initially identified articles, reviews, and commentaries. All references were downloaded for consolidation, elimination of duplicates, and further analyses. Search terms included "angiotensin," "ACE," "ARB," "RAAS," and "COVID-19 or coronavirus." We did not apply language limitations. Two independent and blinded authors (Yujiro Yokoyama and Toshiki Kuno 8 ) reviewed the search results separately to select the studies based on present inclusion and exclusion criteria. Disagreements were resolved by consensus. The study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 9 We conducted two independent analyses. The first analysis investigated the testing positive rate of COVID-19 (positive number/all tested number) for those who were on ACEI and/or ARB and for those who were not on ACEI or ARB. The second analysis investigated in-hospital mortality for patients with COVID-19 treated with ACEI and/or ARB and those not treated with ACEI or ARB. Included studies met the following criteria: the study design was an observational study, the study population included patients with COVID-19, enrolled patients were divided into the ACEI/ARB and no ACEI/ARB groups. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CI, confidence interval; OR, odds ratio. The first meta-analysis assessed the susceptibility to COVID-19 for those who were on ACEI or ARB and showed that the use of ACEI/ARB did not affect the susceptibility to COVID-19. In the second meta-analysis, we observed that the use of ACEI and/or ARB was not associated with a change in in-hospital mortality for patients who were diagnosed with COVID-19. When restricting studies with hypertensive patients only, the use of ACEI and/or ARB was associated with a significant reduction in in-hospital mortality compared with no use of ACEI or ARB. There has been a debate on whether ACEI/ARB should be continued or discontinued for those who were previously treated with ACEI/ARB. Our results support continuous use of the medi- There have been several meta-analyses reported that investigated the effect of ACEI/ARB on COVID-19 patients. [4] [5] [6] However, they included a large observational study using databases in Asia, Europe, and North America, 7 which was retracted from a peerreviewed journal. 27 Since this observational study might have affected the outcomes of these meta-analyses, an updated metaanalysis is warranted to clarify the true effect of ACEI/ARB on COVID-19 patients. Our study has some limitations. First, our analysis included observational studies and is subject to possible selection bias and confounding. However, the sensitivity analysis by removing the outcomes without adjustment methods for the second analysis showed the potential benefit of ACEI/ARB use compared with no use of ACEI/ARB. Therefore, the use of ACEI/ARB is less likely to have a negative impact on in-hospital mortality. Second, we could not analyze severity for COVID-19 such as the ICU admission or intubation rates, since each study used a different definition for severe disease. Similarly, we could not analyze the outcomes of ACEI and ARB separately since few studies reported these separately. In conclusion, our analysis demonstrated that ACEI and/or ARB use was not associated with positive rates of COVID-19, and mortality in COVID-19 patients, but might exert beneficial effects on hypertensive patients with COVID-19. The authors declare that there are no conflict of interests. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Effect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury ACEI/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and metaanalysis Estimation of renin-angiotensin-aldosteronesystem (RAAS)-inhibitor effect on COVID-19 outcome: a metaanalysis A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensinconverting enzyme inhibitors or angiotensin receptor blockers Cardiovascular disease, drug therapy, and mortality in Covid-19 Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Reninangiotensin-aldosterone system blockers and the risk of Covid-19 Association of use of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19) Renin-angiotensinaldosterone system inhibitors and risk of Covid-19 Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality Renin-angiotensinaldosterone system inhibitors and outcome in patients with SARS-CoV-2 pneumonia: a case series study Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study Cardiovascular implications of fatal outcomes of patients with coronavirus disease COVID-19 patients with hypertension have more severity condition, and ACEI/ARB treatment have no influence on the clinical severity and outcome Comparisons of in-patient mortality of COVID-19 for patients with hypertension who were on ACEI and/or ARB and for patients with hypertension who were not on ACEI or ARB. The left portions of the figure show the studies analyzed with their corresponding risk ratio, lower, and upper limits. The right portions of the figure show a forest plot of the data. The horizontal lines represent the values within the 95% confidence interval of the underlying effects. The vertical line indicates a risk ratio of 1. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker Association of renin-angiotensinaldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area Clinical impact of reninangiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for coronavirus disease 2019 Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 Comparative impacts of ACE (angiotensin-converting enzyme) inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19 Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 Association of renin-angiotensinaldosterone system inhibitors with mortality and testing positive of COVID-19: Meta-analysis